News Coverage

 
Click to expand/collapse Dec 15, 2020
Click to open news item in new windowUPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)

Click to expand/collapse Dec 15, 2020
Click to open news item in new windowRafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)

Click to expand/collapse Dec 01, 2020
Click to open news item in new windowRafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue

Click to expand/collapse Dec 01, 2020
Click to open news item in new windowRafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft

Click to expand/collapse Nov 10, 2020
Click to open news item in new windowRafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer

Click to expand/collapse Oct 29, 2020
Click to open news item in new windowFDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma

Click to expand/collapse Oct 27, 2020
Click to open news item in new windowRafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Click to expand/collapse Oct 20, 2020
Click to open news item in new windowA New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals' Lead Compound CPI-613®? (devimistat) for Patients With Pancreatic Cancer in Japan

Click to expand/collapse Aug 06, 2020
Click to open news item in new windowRafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ® (devimistat) for Patients with Metastatic Pancreatic Cancer

Click to expand/collapse Jul 21, 2020
Click to open news item in new windowRafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

 1     2    3   4